Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.
IR Licensing and Partnerships
Latest News
Advertisement
Advertisement
The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve overall survival in patients with advanced of metastatic non-small cell lung cancer who are PD-1 checkpoint inhibitor resistant.
Advertisement
Advertisement
Trending on PharmExec
1
JP Morgan 2026 Wrap Up: Pharma Leaders Speak About the Conference and the State of the Industry
2
Novavax Enters $530 Million License Agreement with Pfizer for Vaccine Development
3
Pharmaceutical Executive Daily: GSK's $2 Billion Acquisition of RAPT Therapeutics
4
The Inflection Point of Pharma and AI: Q&A with Anders Romare
5